Related Experiment Videos
Disk diffusion susceptibility test development for the new glycylcycline, GAR-936
1Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA.
Diagnostic Microbiology and Infectious Disease
|January 8, 2000
Summary
The new glycylcycline GAR-936 shows potent in vitro activity against many common bacterial pathogens, including resistant strains. Disk diffusion susceptibility tests correlate well with MIC results, supporting its clinical development.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Emergence of antibiotic resistance necessitates novel therapeutic agents.
- Tetracyclines are widely used but face resistance challenges.
- Glycylcyclines represent a promising class of antibiotics.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of GAR-936.
- To compare GAR-936 efficacy against tetracyclines.
- To assess disk diffusion susceptibility testing for GAR-936.
Main Methods:
- Broth microdilution and disk diffusion methods were used.
- Nearly 700 recent clinical bacterial isolates were tested.
- GAR-936 activity was compared to two tetracyclines.
Main Results:
- GAR-936 demonstrated potent activity against Gram-positive cocci, including resistant strains.
- It was 2- to 16-fold more active than tetracyclines against Enterobacteriaceae.
- Good agreement was observed between disk diffusion and MIC results.
Conclusions:
- GAR-936 exhibits broad-spectrum in vitro activity against key pathogens.
- Disk diffusion methods are suitable for GAR-936 susceptibility testing.
- GAR-936 is a promising glycylcycline candidate for further clinical development.